May 02, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares over potential securities laws violations by Ironwood Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) concerning whether a series of statements by Ironwood Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Ironwood Pharmaceuticals, Inc. reported that its annual Total Revenue increased from $22.88 million in 2013 to $149.56 million in 2015 and that its respective Net Loss declined from $272.81 million to $142.67 million.

On April 26 2016, a report alleged that contrary to Ironwood Pharmaceuticals claims, Linzess's side effects are not limited to the gastrointestinal (GI) tract, but are instead causing'previously unknown, unreported and unlabeled severe systemic adverse events, including documented cases of rapid weight gain, renal failure, seizures and strokes.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) declined on April 26, 2016, to as low as $9.06 per share.